Prasad Prithiv J, Wormser Gary P
Division of Infectious Diseases, NYU Grossman School of Medicine, 550 First Avenue, New York, NY 10016, USA.
Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA.
Pathogens. 2022 Sep 15;11(9):1051. doi: 10.3390/pathogens11091051.
Although tafenoquine was highly effective for eliminating microscopically detectable parasitemia in mouse models of infection, all of the mice which were assessed developed a relapse of infection, except for those which had been treated concomitantly with artesunate. We report an immunocompromised patient with a similar relapse of parasitemia despite a 46-day course of tafenoquine treatment. More data on whether a longer duration of tafenoquine treatment or using a higher maintenance dose, versus adding a second drug to the regimen, will prevent relapse when tafenoquine is used to treat a highly immunocompromised patient with babesiosis should be investigated.
尽管tafenoquine在小鼠感染模型中对消除显微镜下可检测到的寄生虫血症非常有效，但除了那些同时接受青蒿琥酯治疗的小鼠外，所有接受评估的小鼠都出现了感染复发。我们报告了一名免疫功能低下的患者，尽管接受了46天的tafenoquine治疗，但仍出现了类似的寄生虫血症复发。关于tafenoquine治疗时间延长或使用更高维持剂量，与在治疗方案中添加第二种药物相比，在用于治疗高度免疫功能低下的巴贝斯虫病患者时是否能预防复发，还需要更多的数据来进行研究。
